Bicycle Therapeutics plc
BCYC · NASDAQ
Market closed$4.21$0.030000 (+0.72%)After hours $4.20 · -0.24%
Key statistics
Previous close$4.18
Open$4.15
Day high$4.26
Day low$4.13
52-week high$9.18
52-week low$3.92
Market cap292.15M
Volume183.31K
Average volume450.00K
P/E ratio-1.34
Forward P/E—
EPS-3.15
Dividend yield0.00%
Market context
Why it moved
BCYC edged higher as Bicycle Therapeutics disclosed multiple insider stock option grants to its CFO, COO, and Chief Scientific Officer at an exercise price aligned with the current share price, signaling confidence in the company's outlook among senior leadership.
What is happening
Recent company-specific developments and publisher coverage.
Seeking Alpha · June 1, 2026Bicycle Therapeutics: Trading Below Cash Amid Multiple Uncertainties (NASDAQ:BCYC)Stock Titan · April 21, 2026Five ASCO studies put Bicycle Therapeutics' cancer drug in focusStock Titan · April 20, 2026Bicycle cancer drug hits 40% response rate, enters pancreatic trialInvesting.com · April 20, 2026Bicycle Therapeutics doses first patient in pancreatic cancer trialFierce Biotech · March 17, 2026Hitting regulatory roadblock, Bicycle pumps brakes on lead program and deflates headcount by 30%BioPharma Dive · March 17, 2026Bicycle to lay off 30% of staff, pivot away from Padcev challengerSimply Wall Street · March 17, 2026Bicycle Therapeutics (BCYC) Quarterly Loss Of US$59.1 Million Tests Growth Focus NarrativeBusiness Wire · March 17, 2026Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results Benzinga · May 21, 2026Bicycle Therapeutics' Zelenectide Pevedotin Plus Pembrolizumab Shows SOC-Comparable Response And Improved Safety Profile In Metastatic Urothelial Cancer Phase 2 Study Benzinga · April 30, 2026Bicycle Therapeutics Q1 EPS $(0.87) Misses $(0.73) Estimate, Sales $887.000K Miss $7.267M Estimate Benzinga · April 21, 2026Bicycle Therapeutics Reveals Oral and Poster Presentations At The 2026 ASCO Annual Meeting Benzinga · April 20, 2026Bicycle Therapeutics Issues Updates From Its EphA2 Pipeline At The American Association for Cancer Research (AACR) Annual Meeting 2026 Benzinga · March 18, 2026Citizens Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $8 Mt Newswire · March 18, 2026Oppenheimer Adjusts Bicycle Therapeutics PT to $36 From $44, Maintains Outperform Rating Benzinga · March 17, 2026Bicycle Therapeutics Q4 EPS $(0.29) Beats $(1.00) Estimate, Sales $47.955M Up YoY From $3.708M Mt Newswire · February 3, 2026Bicycle Therapeutics Names Travis Thompson as CFO, Michael Method as Chief Medical Officer